Advice and Support for Cancer Caregivers
Hear from three women breaking new ground in the fields of cancer metastasis, immunology and philanthropy.
How MSK Is Improving CAR T Cell Therapy for Cancer Treatment
Learn how experts at MSK who helped develop CAR T cell therapy to fight cancer are making the treatment stronger, safer, more durable and accessible to more people.
Disrupting a Single Gene Could Improve CAR T Cell Immunotherapy, New Study Shows
Learn how disrupting a gene called SUV39H1 could make CAR T cells more powerful.
Memorial Sloan Kettering Cancer Center Physician-Scientist Michel Sadelain Awarded 2024 Breakthrough Prize in Life Sciences
Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that Michel Sadelain, MD, PhD, renowned physician-scientist, Director of the Center for Cell Engineering, and Stephen and Barbara Friedman Chair, has been awarded the 2024 Breakthrough Prize in Life Sciences.
Testing CRISPR-Edited CAR T Cell Therapy in Lymphoma Clinical Trial
A groundbreaking clinical trial is testing CAR T cells created using CRISPR gene-editing technology.
Clinical Trial for Beta-Thalassemia Brings Important Insights for Treating Blood Disorders with Stem Cell Gene Therapy
A gene therapy approach could prove effective at treating an inherited blood disorder called beta (β)-thalassemia.
In the Lab
A New Target for CAR T Cells: Senescence-Related Diseases
From atherosclerosis and diabetes to liver fibrosis and osteoarthritis, senescent cells are at the root of many debilitating diseases. Scientists increasingly have them in the crosshairs.
World-Renowned Immunologist Michel Sadelain Wins Pasteur-Weizmann/Servier Prize
Michel Sadelain, MD, PhD, Director of the Center for Cell Engineering at MSK, has been awarded the Pasteur-Weizmann/Servier International Prize. Dr. Sadelain was chosen in recognition of his pivotal research demonstrating the therapeutic potential of engineered T cells.
Finding
Adding Low-Dose Radiation Could Make CAR T Therapy More Effective, Study Finds
The treatment combination appears to boost chimeric antigen receptor (CAR) T cells’ ability to kill cancer cells in solid tumors.
In the Clinic
Longest-Running CAR T Trial Shows Which Patients Benefit Most, Have Fewest Side Effects
The study represents 20 years of research at MSK.
In the News
Year in Review: The Science and Technology that Shaped Cancer Care in 2017
As 2017 draws to a close, take a look back at the scientific discoveries that deepened our understanding of cancer in the past year.
In the Clinic
CAR T Cell Therapies Are a Growing Area of Research
Cell therapies that use patients’ own immune cells to attack cancer — including CAR T cell therapy, an approach developed at MSK — are a promising and rapidly growing area of research.
In the Lab
CRISPR Genome-Editing Tool Takes Cancer Immunotherapy to the Next Level
What do you get when you combine two of the hottest areas of biotechnology? A new paper from MSK researchers explains.
Announcement
FDA Approves First CAR T Cell Therapy for Leukemia
Children, teens, and young adults with leukemia that have stopped responding to chemotherapy are the first eligible to receive the new treatment.
In the Clinic
New Trial Advances Cell-Based Immune Therapy for Certain Leukemias
A new study evaluating a cell-based immune therapy to treat an aggressive type of leukemia — the largest study of its kind to date — reports that 88 percent of patients responded to the treatment.
In the News
New Biotech Startup Will Pit the Immune System Against Cancer
Memorial Sloan Kettering’s partnership in a pioneering effort to speed the development of cancer immunotherapies drew national headlines.
Finding
Immunotherapy Shows Promise for Treating Solid Tumors in the Chest
A study in mouse models suggests how modified T cells may be used to treat tumors in the area just outside the lungs.
In the Clinic
Cell-Based Immune Therapy Shows Promise in Leukemia Patients
Memorial Sloan Kettering researchers have used genetically modified immune cells to eradicate cancer in five patients with acute lymphoblastic leukemia.
In the Lab
Genetic “Kill Switch” Could Make Cell Therapies Safer
Researchers have engineered a gene into therapeutic cells that allows them to turn off tumor growth if some of the cells become cancerous.
In the Lab
New Technique Could Make Cell-Based Immune Therapies for Cancer Safer and More Effective
Memorial Sloan Kettering researchers have reported a new method that could allow the development of more-specific, cell-based therapies for cancer.
MSK at ASCO
Memorial Sloan Kettering’s Expertise in Cancer Immunotherapy Draws Media Focus at 2014 ASCO Meeting
Our experts offer their perspective in major media outlets on recent research into drug- and cell-based immunotherapies for cancer.
Announcement
Memorial Sloan Kettering Researchers Appointed to Stand Up To Cancer Immunology “Dream Team”
Physician-scientists Michel Sadelain and Jedd Wolchok have been appointed to a new research team dedicated to investigating ways to harness the immune system to fight cancer.
In the Clinic
Launch of Stem Cell Therapy Trial Offers Hope for Patients with Inherited Blood Disorder
Memorial Sloan Kettering’s trial to evaluate a new therapy for patients with beta-thalassemia is the first to receive FDA approval to treat this disease with genetically engineered cells.
In the Lab
MSK Scientists Fine-Tune CAR T Cells to Improve Their Performance
The updated versions can survive longer in the body while still packing a punch against cancer.
In the Lab
Drug That Hits CAR T Snooze Button Can Quiet a Cytokine Storm
An FDA-approved drug used to treat leukemia can serve as a temporary off switch for CAR T cells, MSK scientists have found.
